- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Organon & Co. Hits New 52-Week Low
Shares of the pharmaceutical company continue to decline amid analyst downgrades.
Mar. 30, 2026 at 7:58pm
Got story updates? Submit your updates here. ›
Shares of Organon & Co. (NYSE:OGN) hit a new 52-week low on Monday, trading as low as $5.76 per share. The stock closed at $5.84, down from its previous close of $5.84. The decline comes as several analysts have downgraded the stock and issued sell ratings.
Why it matters
Organon & Co. is a pharmaceutical company that was spun off from Merck & Co. in 2021. The company's stock has struggled since the spin-off, with shares down over 50% from their initial trading price. The new 52-week low highlights the challenges the company is facing as it works to establish itself as an independent entity.
The details
Organon & Co. has faced a number of headwinds in recent months, including analyst downgrades and concerns about the company's financial performance. Barclays recently raised its price target on the stock to $8.00, but maintained an 'underweight' rating. Meanwhile, Zacks Research downgraded the stock to a 'strong sell' rating, and Wall Street Zen lowered its rating to 'hold'.
- Organon & Co. shares hit a new 52-week low on Monday, March 30, 2026.
- The stock had previously closed at $5.84 on the same day.
The players
Organon & Co.
A global healthcare company that was spun off from Merck & Co. in 2021, focusing on women's health, biosimilars, and established brands.
Barclays
A multinational investment bank that has issued an 'underweight' rating on Organon & Co. shares.
Zacks Research
A research firm that has downgraded Organon & Co. to a 'strong sell' rating.
Wall Street Zen
A financial research and analysis firm that has lowered its rating on Organon & Co. to 'hold'.
The takeaway
The continued decline in Organon & Co.'s stock price and the series of analyst downgrades highlight the challenges the company is facing as it works to establish itself as an independent entity. Investors will be closely watching the company's financial performance and strategic initiatives in the coming months to see if it can turn things around.
